Apparatus and method for modulating neurochemical levels in the brain

• US 8,473,060 B2
• Filed: 12/30/2009
• Issued: 06/25/2013
• Est. Priority Date: 10/05/2004
• Status: Active Grant

• Current Assignee: The Trustees of Dartmounth College (Dartmouth College)
• Original Assignee: The Trustees of Dartmounth College (Dartmouth College)
• Inventors: Leiter, James C., Chernov, Mykyta M., Roberts, David W.
• Primary Examiner(s): Holmes, Rex R
• Application Number:
  US12/649,963
• Publication Number:
  US 20100312305A1
• Time in Patent Office: 1,273 Days
• Field of Search: 600/544, 600/545, 607/45, 607/48
• US Class Current: 607/45
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61N 1/0534 Electrodes for deep brain stimulation
• CPC Class Codes: A61N 1/36082 Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease

Abstract

A treatment for Parkinson'"'"'s Disease uses a stimulus electrode implanted in a subthalamic nucleus with a chemosensor implanted in a globus pallidus pars interna (GPi) of the subject. A level of a neurochemical is sensed with the chemosensor, and compared to a desired level. When the level of the neurochemical is less than desired, an electrical stimulation is provided to the stimulus electrode. In alternative embodiments, the neurochemical sensed is glutamate or dopamine. An alternative system uses a chemosensor implanted in the striatum instead of the GPi. An alternative system for treating benign essential tremor uses a stimulus electrode implanted in the thalamus with feedback taken from a chemosensor in the striatum.

Claims

1. A treatment for a disease in a subject, the disease characterized by low levels of a neurochemical in brain, the treatment comprising:

providing at least one stimulus electrode implanted in a first part of brain of a subject;

providing at least one chemosensor implanted in a second part of brain of the subject;

sensing a level of a neurochemical with the chemosensor;

comparing the level of the neurochemical to a desired level of the neurochemical; and

when the level of the neurochemical is less than the desired level, providing an electrical stimulation to the stimulus electrode;

wherein the electrical stimulation is a high frequency electrical stimulation (HFS) having a pulse rate of at least 100 hertz;

wherein the HFS pulses are provided in bursts, and the bursts are automatically burst-length-modulated in response to chemosensor readings; and

wherein the HFS pulses have a selected pulse parameter selected from the group consisting of voltage or current, and wherein an amplitude of the selected pulse parameter is inversely proportional to the neurochemical level.

2. The treatment of claim 1 wherein the chemosensor is selected from the group consisting of a chemosensor responsive to glutamate levels and a chemosensor responsive to dopamine levels.

3. The treatment of claim 2 further comprising providing a second stimulus electrode implanted in a thalamus of the subject;

providing a second chemosensor implanted in a striatum of the subject;

sensing a second level of a neurochemical with the second chemosensor;

comparing the second level of the neurochemical to a desired level of the neurochemical; and

when the second level of the neurochemical is less than the desired level, providing a second electrical stimulation to the second stimulus electrode.

4. The treatment of claim 3 wherein the second electrical stimulation is a second high frequency electrical stimulation (HFS) having a pulse rate of at least 100 hertz.

5. The treatment of claim 4 wherein the second HFS pulses are provided in bursts, and the bursts are automatically burst-length-modulated in response to chemosensor readings.

6. The treatment of claim 1 wherein the disease is Parkinson'"'"'s Disease.

7. The treatment of claim 6 wherein the chemosensor is selected from the group consisting of a chemosensor responsive to glutamate levels and a chemosensor responsive to dopamine levels.

8. The treatment of claim 7 wherein the chemosensor is located within the GPi.

9. A treatment for a disease in a subject, the disease characterized by low levels of a neurochemical in brain, the treatment comprising:

providing at least one stimulus electrode implanted in a first part of brain of a subject;

providing at least one chemosensor implanted in a second part of brain of the subject;

sensing a level of a neurochemical with the chemosensor;

comparing the level of the neurochemical to a desired level of the neurochemical; and

when the level of the neurochemical is less than the desired level, providing an electrical stimulation to the stimulus electrode;

wherein the electrical stimulation is a high frequency electrical stimulation (HFS) having a pulse rate of at least 100 hertz;

wherein the HFS pulses are provided in bursts, and the bursts are automatically burst-length-modulated in response to chemosensor readings; and

wherein the HFS pulses are provided through a first pair of electrodes when the neurochemical level is low relative to the target level and a second pair of electrodes when the neurochemical level is high.

10. The treatment of claim 9 wherein the disease is Benign Essential Tremor.

11. The treatment of claim 10 wherein the chemosensor is selected from the group consisting of a chemosensor responsive to glutamate levels and a chemosensor responsive to dopamine levels.

12. The treatment of claim 11 further comprising providing a second stimulus electrode implanted in a thalamus of the subject;

providing a second chemosensor implanted in a striatum of the subject;

sensing a second level of a neurochemical with the second chemosensor;

comparing the second level of the neurochemical to a desired level of the neurochemical; and

when the second level of the neurochemical is less than the desired level, providing an electrical stimulation to the second stimulus electrode.

13. The treatment of claim 12 wherein the second electrical stimulation is a second high frequency electrical stimulation (HFS) having a pulse rate of at least 100 hertz.

14. The treatment of claim 12 wherein the second HFS pulses are provided in bursts, and the bursts are automatically burst-length-modulated in response to chemosensor readings.